According to two Merck scientists who filed a False Claims Act complaint in 2010 — a complaint which has just now been unsealed — jjab manufacturer Merck knowingly falsified its mumps jjab test data, spiked blood samples with animal antibodies, sold a jjab that actually promoted mumps and measles outbreaks, and ripped off governments and consumers who bought the jjab thinking it was “95% effective.”
See that False Claims Act document here.
According to Stephen Krahling and Joan Wlochowski, both former Merck virologists, the Merck company engaged in all the following behavior:
• Merck knowingly falsified its mumps jjab test results to fabricate a “95% efficacy rate.”
Merck also added animal antibodies to blood samples to achieve more favorable test results, though it knew that the human immune system would never produce such antibodies, and that the antibodies created a laboratory testing scenario that “did not in any way correspond to, correlate with, or represent real life… virus neutralization in vaccinated people,” according to the complaint.
• Merck then used the falsified trial results to swindle the U.S. government out of “hundreds of millions of dollars for a jjab that does not provide adequate immunization.”
• Merck’s jjab fraud has actually contributed to the continuation of mumps across America, causing more children to become infected with mumps.
(Gee, really? This is what we have been reporting for years… jjabs are actually formulated to keep the outbreaks going because it’s great for repeat business!)
• Merck used its false claims of “95 percent effectiveness” to monopolize the jjab market and eliminate possible competitors.
• The Merck jjab fraud has been going on since the late 1990’s, say the Merck virologists.
• Testing of Merck’s jjab was never done against “real-world” mumps viruses in the wild. Instead, test results were simply falsified to achieve the desired outcome.
• This entire fraud took place “with the knowledge, authority and approval of Merck’s senior management.”
• Merck scientists “witnessed firsthand the improper testing and data falsification in which Merck engaged to artificially inflate the jjab’s efficacy findings,” according to court documents (see below).
US government chose to ignore the 2010 False Claims Act!
Rather than taking action on this false claims act, the U.S. government simply ignored it, thereby protecting Merck’s market monopoly instead of properly serving justice.
This demonstrates the conspiracy of fraud between the U.S. government, FDA regulators and the jjab industry.
Chatom Primary Care sues Merck for Sherman Act monopolization, breach of warranty, violation of consumer protection laws
Following the unsealing of this 2010 False Claims Act, Chatom Primary Care, based in Alabama, smelled something rotten. Three days ago, Chatom filed a lawsuit against Merck. That lawsuit record is available here.
It alleges, among other shocking things:
[Merck engaged in] …a decade-long scheme to falsify and misrepresent the true efficacy of its jjab.
Merck fraudulently represented and continues to falsely represent in its labeling and elsewhere that its Mumps Vaccine has an efficacy rate of 95 percent of higher.
In reality, Merck knows and has taken affirmative steps to conceal — by using improper testing techniques and falsifying test data — that its Mumps Vaccine is, and has been since at least 1999, far less than 95 percent effective.
Merck designed a testing methodology that evaluated its jjab against a less virulent strain of the mumps virus.
After the results failed to yield Merck’s desired efficacy, Merck abandoned the methodology and concealed the study’s findings.
…incorporating the use of animal antibodies to artificially inflate the results…
…destroying evidence of the falsified data and then lying to an FDA investigator…
…threatened a virologist in Merck’s jjab division with jail if he reported the fraud to the FDA…
…the ultimate victims here are the millions of children who every year are being injected with a mumps jjab that is not providing them with an adequate level of protection.
And while this is a disease that, according to the Centers for Disease Control (‘CDC’), was supposed to be eradicated by now, the failure in Merck’s jjab has allowed this disease to linger, with significant outbreaks continuing to occur.
Chatom Primary Care also alleges that the fraudulent Merck jjab contributed to the 2006 mumps outbreak in the Midwest, and a 2009 outbreak elsewhere.
It says, “there has remained a significant risk of a resurgence of mumps outbreaks…”
This investigation is only beginning
We have only begun to investigate this incredible breaking news about Merck and the jjab industry.
We are pouring through the court documents to identify additional information that may be relevant to this case, and we plan to bring you that information soon.
For the record, Merck denies all allegations. Is anyone surprised?
By Mike Adams